Candidemia
📧 Sign up to get email alerts when something new happens for Candidemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-10Clinical Trial Results: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole [Phase 3]
A Phase 3 randomized, double-blind study comparing oral ibrexafungerp versus fluconazole following IV echinocandin for invasive candidiasis …
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. [Phase 3]
Phase 3 trial update of fosmanogepix for treating candidemia and invasive candidiasis in adults; the study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation [Phase 3]
Phase 3 trial evaluating rezafungin versus standard antimicrobial prophylaxis to prevent invasive fungal diseases in adults undergoing allog…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia [Phase 2]
Phase 2 clinical trial evaluating the safety and efficacy of Interferon-gamma 1b in patients with candidemia. The study status is active but…
-
FDA approval · 2026-02-19FDA Approved: VFEND — Supplemental Application (Roerig)
FDA approved a supplemental application for Vfend (voriconazole) submitted by Roerig.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: Non-Conventional Microbiological Methods in the Diagnosis of Candidemia [NA]
A completed clinical trial evaluating non-conventional microbiological methods for the diagnosis of candidemia and invasive candidiasis.
-
FDA approval · 2026-01-21FDA Approved: MICAFUNGIN — Original Application (Hisun Pharmaceuticals USA, Inc.)
FDA approved Hisun Pharmaceuticals USA, Inc.'s original application for micafungin as a generic injectable antifungal. The approval covers u…
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole [Phase 3]
Phase 3, randomized, double-blind trial evaluating ibrexafungerp vs fluconazole after IV echinocandin for invasive candidiasis and candidemi…
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Performance Evaluation of the Fujifilm Wako Beta-D-glucan Technique in the Diagnosis of Major Invasive Fungal Infections (IFI)
This clinical trial update evaluates the performance of the Fujifilm Wako beta-D-glucan assay in diagnosing major invasive fungal infections…
-
FDA approval · 2025-11-14FDA Approved: VORICONAZOLE — Original Application (Hainan Poly Pharm. Co., Ltd.)
The FDA approved a generic Voriconazole product from Hainan Poly Pharm. Co., Ltd. via an Original Application (ANDA 220043). It covers voric…
-
FDA approval · 2025-07-23FDA Approved: MICAFUNGIN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Micafungin (Hikma Pharmaceuticals USA Inc.), leading to changes/updates approved for this antifu…
-
FDA approval · 2025-07-18FDA Approved: CASPOFUNGIN ACETATE — Original Application (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
The FDA approved Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.'s caspofungin acetate as an original generic application (ANDA) for mark…
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia
This clinical trial compares a 7-day short-course antifungal therapy to the standard 14-day regimen for uncomplicated candidemia; the study …
-
FDA approval · 2025-04-03FDA Approved: MICAFUNGIN — Original Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark's original ANDA for generic micafungin for the treatment of invasive candidiasis, candidemia, esophageal candidiasis, …
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: A Randomized Study of a Short Duration Therapy for Candidemia [Phase 3]
A Phase 3 randomized trial is evaluating a short-duration therapy for candidemia; the study is currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia [Phase 4]
A Phase 4 trial evaluating micafungin for invasive candidiasis or candidemia was terminated.
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug [Phase 1]
Phase 1 study of Mycamine in children to evaluate safety and drug blood levels in fungal infections; the trial has completed.
-
CLINICAL_TRIALS research · 2024-11-18Clinical Trial Update: A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis [Phase 2]
A Phase 2 clinical trial is evaluating intravenous HRS9432 for the treatment of candidemia and/or invasive candidiasis and is currently recr…
-
CLINICAL_TRIALS research · 2024-08-02Clinical Trial Update: Candida PCR Diagnosis Strategy in Patients From Intensive Care Units [NA]
This clinical trial update describes a study evaluating a Candida PCR diagnostic strategy in ICU patients to improve detection of Candida in…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) [Phase 3]
Phase 3 open-label study evaluating oral ibrexafungerp (SCY-078) for invasive candidiasis and candidemia caused by Candida auris was complet…
-
CLINICAL_TRIALS trial_result · 2024-06-25Clinical Trial Update: Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis [Phase 2]
Phase 2 trial comparing oral ibrexafungerp (SCY-078) to standard-of-care after IV echinocandin in invasive candidiasis; study completed with…
-
CLINICAL_TRIALS withdrawal · 2024-06-14Clinical Trial Update: Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients [Phase 4]
Phase 4 trial comparing fluconazole versus micafungin for candidemia in non-neutropenic patients has been withdrawn.
-
FDA approval · 2023-09-29FDA Approved: MICAFUNGIN IN SODIUM CHLORIDE — Original Application (Baxter Healthcare Corporation)
FDA approved a new intravenous micafungin sodium formulation under Baxter's Original Application NDA, expanding antifungal treatment options…
-
FDA approval · 2023-03-22FDA Approved: REZZAYO — Original Application (Melinta Therapeutics, LLC)
FDA approved the original application for REZZAYO (rezafungin) by Melinta Therapeutics for the treatment of candidemia and invasive candidia…
-
CLINICAL_TRIALS trial_result · 2023-01-09Clinical Trial Update: An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris [Phase 2]
Open-label Phase 2 trial evaluating APX001 (fosmanogepix) for candidemia and invasive candidiasis caused by Candida auris; study completed w…